Literature DB >> 1793211

Photopheresis for rheumatoid arthritis.

S E Malawista1, D Trock, R L Edelson.   

Abstract

For rheumatoid arthritis, an effective therapy with minimal toxicity would be welcome. In a six-month pilot study of seven patients with a variety of presentations and previous treatments, we tested a therapy involving the extracorporeal photoactivation of biologically inert methoxsalen (8-methoxypsoralen) by ultraviolet A energy to a form that covalently cross-links lymphocyte DNA; the injured cells are returned to the patient. Prior experimental studies had indicated that this regimen produces an immune reaction against antigens on treated T Cells, and a clinical trial in cutaneous T cell lymphoma had been successful. The current patients were treated on two successive days monthly (or, later on, biweekly). Between 12 and 16 weeks of therapy there appeared to be a breakpoint after which joint counts and joint scores of four patients began to improve. In three of them, these measures eventually diminished by mean values of 71% and 80%, respectively, of their baseline values, along with variable improvement in less direct indicators of clinical response. The joints of the fourth patient improved modestly (by 33% and 59%, respectively, of baselines) but he required alternative therapy, and those of the remaining three patients did not improve. Mean slopes for the joint counts were significantly different from zero after the apparent breakpoint (but not before), whether one examined the four apparent responders (p = 0.01) or the entire group of seven (p = 0.01). After completion of therapy, there was also a delay, of two to three months, in the clinical deterioration of those who had improved. There was only one mechanical adverse effect--a single episode of transient hypotension in 102 treatment sessions--and no toxic ones. This preliminary study suggests that extracorporeal photochemotherapy may be effective at least in the short term in certain patients with rheumatoid arthritis, with less apparent toxicity than that of any of the drugs currently used for this disorder. It deserves further evaluation.

Entities:  

Mesh:

Year:  1991        PMID: 1793211     DOI: 10.1111/j.1749-6632.1991.tb33453.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Phototherapy--T cell vaccination by any other name?

Authors:  G S Panayi
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

Review 2.  Extracorporeal photopheresis as a therapy for autoimmune diseases.

Authors:  Zoya Kuzmina; David Stroncek; Steven Z Pavletic
Journal:  J Clin Apher       Date:  2014-12-26       Impact factor: 2.821

3.  Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.

Authors:  C Dou; Y Chen; N Ding; N Li; H Jiang; C Zhao; F Kang; Z Cao; H Quan; F Luo; J Xu; S Dong
Journal:  Osteoporos Int       Date:  2016-01-25       Impact factor: 4.507

4.  Normal oxidative activity and chemotaxis of circulating neutrophils in patients treated with photopheresis.

Authors:  N Obel; M Storgaard; B Hansen; H Zachariae
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

5.  Anti-tumor effects of various furocoumarins isolated from the roots, seeds and fruits of Angelica and Cnidium species under ultraviolet A irradiation.

Authors:  Maho Sumiyoshi; Masahiro Sakanaka; Masahiko Taniguchi; Kimiye Baba; Yoshiyuki Kimura
Journal:  J Nat Med       Date:  2013-05-07       Impact factor: 2.343

Review 6.  Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis.

Authors:  Philippe Saas; Francis Bonnefoy; Eric Toussirot; Sylvain Perruche
Journal:  Front Immunol       Date:  2017-10-09       Impact factor: 7.561

7.  Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept.

Authors:  Céline Coppard; Francis Bonnefoy; Dalil Hannani; Françoise Gabert; Olivier Manches; Joel Plumas; Sylvain Perruche; Laurence Chaperot
Journal:  J Transl Med       Date:  2019-09-18       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.